公开(公告)号：AU2019344300A1

公开(公告)日：2021-04-22

申请号：AU2019344300

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS N V

Inventor： VAN DER VLIET JOHANNES JELLE ,  LAMERIS ROELAND ,  DE GRUIJL TANJA DENISE ,  PARREN PAUL WILLEM HENRI IDA

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/04

Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T- cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri-or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-,and tri-or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.

公开(公告)号：MX386714B

公开(公告)日：2025-03-11

申请号：MX2017009680

申请日：2017-07-26

Applicant: LAVA THERAPEUTICS N V

Inventor： VERHEUL HENDRIK MARINUS WILLEM ,  VAN DER VLIET JOHANNES JELLE ,  DE BRUIN RENÉE CORNELIA GERARDA ,  LAMERIS ROELAND ,  DE GRUIJL TANJA DENISE

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/04 ,  C07K16/30

Abstract: La presente invención se refiere a compuesto, en particular a polipéptidos que se unen específicamente a la proteína MHC no clásica CD1d y modulan las funciones biológicas mediadas por CD1d; la invención en particularmente relacionada a tales compuestos y polipéptidos que comprenden o consisten en al menos un anticuerpo de dominio simple se une específicamente a CD1d; también se proporcionan métodos y el uso empleando tales compuestos, polipéptidos y/o anticuerpos de dominio simple.

公开(公告)号：IL317337A

公开(公告)日：2025-01-01

申请号：IL31733724

申请日：2024-11-28

Applicant: LAVA THERAPEUTICS N V ,  PARREN PAUL WILLEM HENRI IDA ,  ROOVERS ROBERTUS CORNELIS ,  VAN DER VLIET JOHANNES JELLE ,  LUTJE HULSIK DAVID ,  MACHIELSEN PETER ALEXANDER GERARDUS MARIA ,  VAN WESTERHOVEN MICHIEL ,  KING LISA ANNA ,  FENNEMANN FELIX LENNART ,  MOUSSET CHARLOTTE MERETTE ,  ADANG ANTON EGBERT PETER

Inventor： PARREN PAUL WILLEM HENRI IDA ,  ROOVERS ROBERTUS CORNELIS ,  VAN DER VLIET JOHANNES JELLE ,  LUTJE HULSIK DAVID ,  MACHIELSEN PETER ALEXANDER GERARDUS MARIA ,  VAN WESTERHOVEN MICHIEL ,  KING LISA ANNA ,  FENNEMANN FELIX-LENNART ,  MOUSSET CHARLOTTE MERETTE ,  ADANG ANTON EGBERT PETER

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to antibodies capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：AU2016212777B2

公开(公告)日：2021-11-18

申请号：AU2016212777

申请日：2016-01-27

Applicant: LAVA THERAPEUTICS N V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE GRUIJL TANJA DENISE ,  VERHEUL HENDRIK MARINUS WILLEM ,  DE BRUIN RENEE CORNELIA GERARDA ,  LAMERIS ROLAND

IPC: C07K16/28

Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.

公开(公告)号：EA039086B1

公开(公告)日：2021-12-01

申请号：EA201692039

申请日：2015-04-10

Applicant: LAVA THERAPEUTICS N V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE BRUIN RENEE CORNELIA GERARDA ,  DE GRUIJL TANJA DENISE ,  VERHEUL HENDRIK MARINUS WILLEM

IPC: C07K16/28

Abstract: Изобретениеотноситсяк областимедициныи кобластииммунологии, ив частностиотноситсяк молекулеиммуноглобулина, связывающейчеловеческий V9V2 Т-клеточныйрецептор, нуклеотиднойпоследовательности, котораякодируетмолекулуиммуноглобулина, клетке-хозяину, содержащейуказаннуюнуклеотиднуюпоследовательность, способуполучениямолекулыиммуноглобулина, биспецифическомуантителу, применениюбиспецифическогоантителаприлечениирака, применениюмолекулыиммуноглобулинадляактивациичеловеческих V9V2 Т-клеток.

公开(公告)号：AU2015244489B2

公开(公告)日：2020-08-27

申请号：AU2015244489

申请日：2015-04-10

Applicant: LAVA THERAPEUTICS N V

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE BRUIN RENEE CORNELIA GERARDA ,  DE GRUIJL TANJA DENISE ,  VERHEUL HENDRIK MARINUS WILLEM

IPC: C07K16/28

Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor bindingimmunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.

公开(公告)号：MX385333B

公开(公告)日：2025-03-18

申请号：MX2016013332

申请日：2016-10-10

Applicant: LAVA THERAPEUTICS N V

Inventor： VERHEUL HENDRIK MARINUS WILLEM ,  VAN DER VLIET JOHANNES JELLE ,  DE BRUIN RENÉE CORNELIA GERARDA ,  DE GRUIJL TANJA DENISE

IPC: C07K16/28 ,  A61P35/00

Abstract: La presente invención se refiere a está en el campo de la medicina y se refiere a la inmunología, y se refiere en particular a moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas; las moléculas de inmunoglobulina que se unen al receptor de célula T V?9Vd2 humanas son en particular para su uso en el tratamiento médico y/o útiles en pruebas con células T V?9Vd2 humanas, en donde la células T V?9Vd2 humanas pueden ser moduladas.

公开(公告)号：AU2023293961A1

公开(公告)日：2024-12-19

申请号：AU2023293961

申请日：2023-06-15

Applicant: LAVA THERAPEUTICS N V

Inventor： PARREN PAUL WILLEM HENRI IDA ,  ROOVERS ROBERTUS CORNELIS ,  VAN DER VLIET JOHANNES JELLE ,  LUTJE HULSIK DAVID ,  MACHIELSEN PETER ALEXANDER GERARDUS MARIA ,  VAN WESTERHOVEN MICHIEL ,  KING LISA ANNA ,  FENNEMANN FELIX-LENNART ,  MOUSSET CHARLOTTE MERETTE ,  ADANG ANTON EGBERT

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to antibodies capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：AU2023288542A1

公开(公告)日：2024-12-19

申请号：AU2023288542

申请日：2023-06-23

Applicant: LAVA THERAPEUTICS N V

Inventor： RIEDL THILO ALEXANDER ,  HOENDERDOS KIM ,  ADANG ANTON EGBERT PETER ,  VAN DER VLIET JOHANNES JELLE

IPC: G01N33/569 ,  C12N5/0783

Abstract: The present disclosure provides reporter T cells expressing a γδ T cell receptor (TCR) and a reporter gene, wherein the reporter gene is expressed when the T cell is activated. Also provided are assays that utilize the modified T cells to detect and/or quantitate T cell dependent binding compounds directed to a γδTCR and a target antigen and to determine the relative potency of such binding compounds.

公开(公告)号：IL316588A

公开(公告)日：2024-12-01

申请号：IL31658824

申请日：2024-10-28

Applicant: LAVA THERAPEUTICS N V ,  PARREN PAUL WILLEM HENRI IDA ,  ROOVERS ROBERTUS CORNELIS ,  VAN DER VLIET JOHANNES JELLE ,  LUTJE HULSIK DAVID ,  MACHIELSEN PETER ALEXANDER GERARDUS MARIA ,  VAN WESTERHOVEN MICHIEL ,  KING LISA ANNA ,  FENNEMANN FELIX LENNART ,  VAN DER VEEN JOCHEM WILLEM

Inventor： PARREN PAUL WILLEM HENRI IDA ,  ROOVERS ROBERTUS CORNELIS ,  VAN DER VLIET JOHANNES JELLE ,  LUTJE HULSIK DAVID ,  MACHIELSEN PETER ALEXANDER GERARDUS MARIA ,  VAN WESTERHOVEN MICHIEL ,  KING LISA ANNA ,  FENNEMANN FELIX-LENNART ,  VAN DER VEEN JOCHEM WILLEM

IPC: A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to pharmaceutical compositions comprising antibodies capable of binding a human Vγ9Vδ2 T cell receptor. The invention further relates to uses of the pharmaceutical compositions of the invention for medical treatment.